Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1716421

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she (a) has had and (b) plans to have with (i) charities and (ii) other organisations working to secure UK access to new drugs for (A) incurable, (B) relapsing and (C) remitting cancers such as myeloma.
tabling member constituency	Birmingham, Yardley
tabling member printed	Jess Phillips
uin	25238
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>Department ministers and officials regularly meet with a range of organisations, with an interest in securing patient access to new cancer medicines. The National Institute for Health and Care Excellence (NICE) is the body that develops authoritative, evidence-based guidance for the National Health Service on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits, including medicines for myeloma. The NICE aims to publish guidance on all new medicines close to the point of licensing wherever possible, and has recommended many cancer medicines for NHS use that are now available to NHS patients, including through the Cancer Drugs Fund.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:43:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4370 label Biography information for Jess Phillips

1688273

registered interest
date	07/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she (a) has had and (b) plans to have with (i) brain tumour research charities and (ii) other organisations working to secure UK access to (A) Vorasidenib and (B) other new drugs for cancers of unmet need.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	13599
answer	answer is ministerial correction date of answer 19/02/2024 answer text <p>Department ministers and officials regularly meet with charities and other organisations working to improve outcomes for patients with cancer, including brain tumours, through access to new medicines.</p><p>The National Institute for Health and Care Excellence (NICE) makes recommendations on whether all new medicines should be routinely funded by the National Health Service based on an assessment of their costs and benefits and aims to publish guidance as close as possible to licensing. NICE engages with stakeholders, including charities, in the development of its recommendations. NICE is currently developing guidance for the NHS on the use of Vorasidenib.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/02/2024 09:35:53 answering member 4044 label Biography information for Andrew Stephenson
tabling member	3930 label Biography information for Caroline Lucas

1681620

registered interest
date	11/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she is having with pharmaceutical organisations on releasing drugs for clinical trials for the treatment of less survivable cancers.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	9252
answer	answer is ministerial correction date of answer 17/01/2024 answer text <p>In March 2021, the Government published Saving and Improving Lives: The Future of UK Clinical Research Delivery, setting out ambitions to reform clinical research delivery in the United Kingdom. This sets out how we will improve patient access to clinical trials in all areas, including cancer. This, together with the Government response to the O’Shaughnessy review backed by up to £121 million of funding, will help to drive improvements in recruitment to clinical trials and approval processes which lead to quicker study set up. Implementation of our vision for clinical trials brings together stakeholders from across the research system, including industry, and we continue to have regular engagement with industry partners through established forums.</p><p>The UK’s Cancer Mission, a key element of the Life Sciences Vision, will also bring together industry, academia, and the National Health Service to collaborate and make progress on cancer, including by driving the development and commercialisation of new cancer medicines.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/01/2024 17:29:10 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1659541

registered interest
date	11/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his Department's planned timescale is for the (a) approval and (b) rollout of the AOH1996 drug through the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	198709
answer	answer is ministerial correction date of answer 19/09/2023 answer text <p>There is currently no planned timescale for the approval and rollout of the AOH1996 drug through the National Health Service as the Medicines and Healthcare products Regulatory Agency (MHRA) has not granted a marketing authorisation for AOH1996. Should an application be received, the MHRA has a number of licensing pathways available, with the aim of ensuring the products can be made available for patients in the United Kingdom in the shortest time possible and to support and protect public health.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/09/2023 12:56:54 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1653028

registered interest
date	13/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to ensure that more cancer drugs can transition from a Phase 1 study to Medicines and Healthcare products Regulatory Agency (MHRA) approval.
tabling member printed	Lord Hunt of Kings Heath
uin	HL9329
answer	answer is ministerial correction date of answer 20/07/2023 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is aware that customers who have submitted initial applications and amendments to our Clinical Investigations and Trials team have experienced extended timeframes in some cases, and understands how this unpredictability may be reducing the number of cancer drugs that can transition from a Phase 1 study to MHRA approval. To help improve the predictability of decision making in applications for clinical trials, the MHRA have implemented several actions.</p><p>The MHRA are looking at novel ways to develop staff capability and expertise. New assessor capacity is being supplemented with an additional fixed-term resource of appropriately experienced and qualified specialists to support the training and supervision of new staff and to help reduce the current backlog. The MHRA has also established links with the Association of the British Pharmaceutical Industry and the BioIndustry Association on clinical trials, to reduce the backlog of delayed applications, which may include applications for cancer drugs. Additionally, they have already reallocated work, and are evaluating queued applications for complexity, to improve the speed of assessment, and are changing processes to take a joined-up risk-proportionate approach.</p><p>The MHRA is committed to reducing these backlogs so that it makes regulatory decisions in accordance with statutory timeframes for all new fully compliant clinical trial applications received from 1 September 2023. This will enable more cancer drugs to progress from Phase 1 studies to MHRA approval where appropriate.</p> answering member printed Lord Markham question first answered 20/07/2023 16:33:27 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1644841

registered interest
date	14/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which cancer medicines have received (a) an innovation passport and (b) other support under the Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway; and if he will make an assessment of the impact of the pathway on the time taken for innovative treatments to become available to patients.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Paula Barker
uin	189731
answer	answer is ministerial correction date of answer 23/06/2023 answer text <p>The Innovative Licensing and Access Pathway (ILAP) was launched in January 2021, and has seen strong interest from both small and large companies in a variety of therapeutic settings. Companies who successfully gain an Innovation Passport designation are able to apply for the next step; the Target Development Profile. There are currently 55 cancer drugs that have been awarded an innovation passport as part of the Innovative Licensing and Access Pathway. Eight of these products have accessed the Target Development Profile and a further seven are in progress.</p><p>Holding an innovation passport is required to apply for Project Orbis. Project Orbis provides a framework for concurrent submission and review of oncology products among international partners, aiming to deliver faster patient access to innovative cancer treatments. 27 innovation passport holders have applied for Project Orbis.</p><p>Following the McLean report there is ongoing work to ensure enhanced speed and efficiency of ILAP.</p> answering member constituency Colchester answering member printed Will Quince question first answered 23/06/2023 13:29:04 answering member 4423 label Biography information for Will Quince
tabling member	4828 label Biography information for Paula Barker

1644842

registered interest
date	14/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which cancer medicines are being reviewed by the Medicines and Healthcare products Regulatory Agency under Project Orbis as of 14 June 2023.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Paula Barker
uin	189732
answer	answer is ministerial correction date of answer 23/06/2023 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) does not publish details on applications currently under review as this is considered commercially sensitive information. That said, details of the products approved by the MHRA under Project Orbis are published on the MHRA website available at the following link:</p><p><a href="https://www.gov.uk/guidance/guidance-on-project-orbis#overview-of-orbis-project-approvals" target="_blank">https://www.gov.uk/guidance/guidance-on-project-orbis#overview-of-orbis-project-approvals</a></p> answering member constituency Colchester answering member printed Will Quince question first answered 23/06/2023 13:51:30 answering member 4423 label Biography information for Will Quince
tabling member	4828 label Biography information for Paula Barker

1644210

registered interest
date	13/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 June 2023 to Question 185884 on Cancer: Drugs, whether NHS England plans to publish the recommendations of its task and finish group establishing systemic anti-cancer therapies delivery capacity.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	189229
answer	answer is ministerial correction date of answer 19/06/2023 answer text <p>At present, NHS England does not plan to publish the recommendations from its task and finish group establishing systemic anti-cancer therapies delivery capacity. NHS England will use the recommendations to inform next steps so that people with cancer continue to access the best possible care. In reviewing the recommendations of the task and finish group, NHS England will consider whether additional funding and resources are necessary.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 189230 question first answered 19/06/2023 16:26:54 answering member 4527 label Biography information for Helen Whately
tabling member	3973 label Biography information for Grahame Morris

1644211

registered interest
date	13/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 June 2023 to Question 185884 on Cancer: Drugs, what funding and resources will be available to support the recommendations generated by NHS England’s task and finish group looking at service capacity for systemic anti-cancer therapies.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	189230
answer	answer is ministerial correction date of answer 19/06/2023 answer text <p>At present, NHS England does not plan to publish the recommendations from its task and finish group establishing systemic anti-cancer therapies delivery capacity. NHS England will use the recommendations to inform next steps so that people with cancer continue to access the best possible care. In reviewing the recommendations of the task and finish group, NHS England will consider whether additional funding and resources are necessary.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 189229 question first answered 19/06/2023 16:26:54 answering member 4527 label Biography information for Helen Whately
tabling member	3973 label Biography information for Grahame Morris

1639205

registered interest
date	22/05/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of providing funding to NHS England for (a) drug administration, (b) the management of side effects, (c) standardised delivery and (d) other costs for every approved Systemic Anti-Cancer Therapy regime.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	186071
answer	answer is ministerial correction date of answer 26/05/2023 answer text <p>No assessment has been made. NHS England is the responsible commissioner for systemic anti-cancer therapies.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 26/05/2023 13:18:53 answering member 4527 label Biography information for Helen Whately
tabling member	3973 label Biography information for Grahame Morris